The recent US-UK pharmaceutical trade agreement has sparked intense debate across Britain, with a new analysis published in the British Medical Journal highlighting potential severe consequences for the National Health Service and public health outcomes.
Announced in December 2025, the deal was positioned by the UK government as a landmark achievement that would protect British medicine exports from tariffs while enhancing patient access to innovative treatments. However, independent modelling suggests it could impose substantial additional costs on the NHS, forcing difficult choices about resource allocation.
Background to the Agreement
The agreement emerged from broader trade negotiations between the two nations following the US presidential election. It secures zero tariffs on UK pharmaceutical and medical device exports to the United States for three years. In exchange, the UK committed to reforms in drug pricing and health technology assessment processes that would increase spending on new branded medicines supplied largely by American companies.
Officials described the pact as a boost for the life sciences sector and a way to secure better medicines for patients. The changes include adjustments to the threshold used by the National Institute for Health and Care Excellence and modifications to rebate mechanisms, effectively raising the amount the NHS pays for certain pharmaceuticals.
Key Findings from the BMJ Analysis
The peer-reviewed analysis estimates that the cumulative additional cost to the English NHS could reach approximately £45 billion by the end of 2036. Without corresponding increases in overall NHS funding, this extra expenditure would require diverting resources from other services such as staffing, equipment, and routine care.
Researchers modelled the opportunity costs of these reallocations. They concluded that the direct impact on NHS services could result in roughly 229,000 excess deaths by 2036. When indirect effects on adult social care are included, the figure rises to around 291,000. For context, this exceeds the number of COVID-19 deaths recorded in England between March 2020 and June 2022, which stood at approximately 137,000.
The study emphasises that these projections stem from reduced spending on non-drug health services, leading to poorer outcomes in areas like cancer care, cardiovascular treatment, and emergency response.
Economic Pressures on the NHS
The National Health Service already operates under significant financial strain. The additional drug costs would more than double the proportion of GDP allocated to new medicines over the coming decade. This shift occurs at a time when the service faces rising demand from an ageing population and ongoing recovery from the pandemic.
Health economists involved in the analysis describe the situation as creating unavoidable trade-offs. Funds directed toward higher-priced pharmaceuticals leave less available for preventive programmes, diagnostic services, and workforce expansion. The modelling assumes no supplementary government funding to offset the increases.
Stakeholder Perspectives
Government ministers have defended the agreement, arguing it safeguards export markets for British pharmaceutical firms and accelerates access to cutting-edge therapies. They maintain that long-term economic benefits from a strengthened life sciences industry will ultimately support healthcare funding.
Critics, including health policy experts and opposition figures, contend that the deal prioritises pharmaceutical industry interests over patient welfare. They point to the lack of transparent parliamentary scrutiny during negotiations and question whether the projected health gains justify the scale of potential harm.
Patient advocacy groups have expressed concern that reduced funding elsewhere could disproportionately affect vulnerable populations, widening existing health inequalities across regions and socioeconomic groups.
Public Health Implications
The projected excess deaths would arise from multiple pathways. Delayed treatments, shorter hospital stays, reduced community care, and fewer investments in public health initiatives all contribute to the modelled outcomes. The analysis isolates the effects of funding diversion to demonstrate the scale of the challenge.
Regional variations are likely, with areas already experiencing higher deprivation facing amplified risks. The study highlights how opportunity costs in healthcare translate into measurable population-level impacts over an 11-year horizon.
Broader Context and Comparisons
This development occurs against a backdrop of post-Brexit trade realignments and evolving US-UK relations. Similar concerns have arisen in other sectors where trade-offs between market access and domestic service provision have emerged.
International observers note that the UK approach to pharmaceutical pricing has historically balanced innovation incentives with affordability. The new commitments represent a notable departure that could influence future negotiations with other trading partners.
Potential Pathways Forward
Policy responses under discussion include calls for additional Treasury allocations to cover the increased drug costs, renegotiation of specific terms, or enhanced efficiency measures within the NHS to absorb the pressure. Some analysts suggest greater transparency in future trade talks could help mitigate unintended consequences.
Independent reviews of the modelling and ongoing monitoring of NHS expenditure patterns are also recommended to inform adjustments as the agreement unfolds.
Future Outlook
As implementation progresses, the full effects on service delivery and health outcomes will become clearer. The debate underscores the complex interplay between trade policy, pharmaceutical economics, and the sustainability of publicly funded healthcare systems.
Stakeholders across government, industry, and civil society continue to engage with the findings, seeking balanced approaches that support both economic growth and population health.